CClinicalTrials.gg
CompletedNCT03698604Updated Oct 9, 2018

Total Laparoscopic Hysterectomy Versus Total Abdominal Hysterectomy in Women With Endometrial Neoplasia

An interventional study of Hysterectomy in Hysterectomy and Laparoscopy, sponsored by Ain Shams Maternity Hospital. Completed at 1 site in Egypt. Open to female participants. Per ClinicalTrials.gov, last updated 2018-10-09.

Sponsored by Ain Shams Maternity Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2018, registered Sep 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Sex
Female
01

Study summary

The aim of this study is to compare operative time between total laparoscopy hysterectomy with bilateral salpingoophrectomy (TLH+BSO) versus total abdominal hysterectomy and bilateral salpingooophorectomy (TAH+BSO) in women with uterine neoplasia.

Read the detailed description

Research Questions:

Is total laparoscopic hysterectomy associated with similar operative operative time as total abdominal hysterectomy and bilateral salpingoophrectomy in women with uterine neoplasia?

Research Hypothesis:

In women with uterine neoplasia TLH with BSO may be similar to TAH with BSO as regard operative time.

02

Conditions studied

  • Hysterectomy
  • Laparoscopy
03

In context

Endometrial Neoplasms

1,325 studies on the registry are indexed under Endometrial Neoplasms; 447 are open to participants now.

This study's enrollment of 52 is below the median of 70 across 941 interventional studies indexed under Endometrial Neoplasms.

Browse Endometrial Neoplasms studies →

Lead sponsor

Ain Shams Maternity Hospital is the lead sponsor of 135 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

The presence of perimenopausal bleeding

  • Early stage endometrial carcinoma.
  • Endometrial hyperplasia with/without atypia.

Exclusion criteria

Exclusion Criteria:

  • Obese patients i.e., BMI\< 29 k.g/m2.
  • Patients unfit for laparoscopy as patients with cardio-pulmonary compromise.
  • Presence of adnexal mass.
  • End stage endometrial carcinoma stage 3 \& 4.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Active comparator
    Total Laparoscopic Hysterectomy

    The group that will undergo total laparoscopy hysterectomy with bilateral salpingoophrectomy.

    Procedure: Hysterectomy

  • Active comparator
    Total Abdominal hysterectomy

    The group that will undergo total abdominal hysterectomy with bilateral salpingoophrectomy.

    Procedure: Hysterectomy

Interventions

  • ProcedureHysterectomy

    Total Laparoscopic Hysterectomy Total Abdominal hysterectomy

06

What researchers measure

Primary outcomes

  1. Operative time

    Operative time measured in minutes using stopwatch excluding time of concomitant surgical procedures.

    Time frame: From skin incision till closure of the vault "up to 4 hours".

Secondary outcomes

  1. Blood loss

    Intra operative blood loss will be estimated via: 1. Amount of blood in the suction bottle. 2. Estimation will be based on number of soaked gauzes and towels (soaked gauze = 20 ml blood; soaked towel = 150 ml; semi soaked towel = 75 ml).

    Time frame: From skin incision start until skin suturing is finished "up to 4 hours".

  2. Blood transfusion

    The need to blood transfusion to the patient.

    Time frame: From admission to the hospital until the home discharge "up to 1 week".

  3. Postoperative pain

    Assessment of pain intensity using Visual Analog Scale (VAS) which is one-dimensional measure of pain intensity. It is a continuous scale comprised of a horizontal line, 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. The scale is anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100).

    Time frame: 8 hours after the end of operation.

  4. Hospital stay

    Hospital stay duration in days.

    Time frame: From admission to the hospital until the home discharge "up to 1 week".

  5. Incidence of operative complications

    The need for laparotomy, and bowel or bladder or ureteric injury.

    Time frame: During operation.

  6. Incidence of postoperative complications

    Morbidities e.g.: * Vaginal vault hematoma or pelvic hematoma or abscess. * Surgical site infection. * Urinary tract infection. * Need for post-operative blood transfusion. * Postoperative bowel or urinary tract complications.

    Time frame: Up to 1 week postoperative.

07

Study locations

1 site
  • Ain Shams Maternity Hospital
    Cairo, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03698604
Lead sponsor
Ain Shams Maternity Hospital
Responsible party
Rania Gamal Anwar Elskaan (Assistant Lecturer, Ain Shams Maternity Hospital) — Principal investigator
First posted
Oct 9, 2018
Start date
Jan 1, 2018
Primary completion
May 1, 2018
Completion
Aug 1, 2018
Last update
Oct 9, 2018

Study contacts

Walid E Mohammed, MD
study director · Ain Shams Maternity Hospital
Mortada E Ahmed, MD
study director · Ain Shams Maternity Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion